|
|
Active Org.- |
|
Active Indication- |
|
Drug Highest PhaseUnknown |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Multicenter, Active Control, Parallel Group, Randomized, Double-blind, Phase II Clinical Trial to Evaluate the Efficacy and Safety of SCAI-001 Eye Drops in Patients With Dry Eye Disease
This study is planned to Evaluate the Efficacy and Safety of SCAI-001 Eye Drops(Cyclosporine 0.01%, 0.02%) compared to Restasis(Cyclosporine 0.05%) in Patients with Dry Eye Disease.
100 Clinical Results associated with SCAI Therapeutics Co., Ltd.
0 Patents (Medical) associated with SCAI Therapeutics Co., Ltd.
100 Deals associated with SCAI Therapeutics Co., Ltd.
100 Translational Medicine associated with SCAI Therapeutics Co., Ltd.